Wedbush Starts Unum Therapeutics (UMRX) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises in broad rebound; yields push markets towards weekly declines
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
- SpaceX shares fall as second lockup period ends
SunTrust Robinson Humphrey Starts Unum Therapeutics (UMRX) at Buy
April 23, 2018 6:22 AM EDTSunTrust Robinson Humphrey initiates coverage on Unum Therapeutics (NASDAQ: UMRX) with a Buy rating and a price target of $21.00.
For an analyst ratings summary and ratings history on Unum Therapeutics click here. For more ratings news on Unum Therapeutics click here.
Shares of Unum Therapeutics closed at $11.98 Friday.
... MoreMorgan Stanley Starts Unum Therapeutics (UMRX) at Overweight
April 23, 2018 5:35 AM EDTMorgan Stanley initiates coverage on Unum Therapeutics (NASDAQ: UMRX) with a Overweight rating and a price target of $20.00.
For an analyst ratings summary and ratings history on Unum Therapeutics click here. For more ratings news on Unum Therapeutics click here.
Shares of Unum Therapeutics closed at $11.98 Friday.
... MoreCowen Starts Unum Therapeutics (UMRX) at Market Perform
April 23, 2018 5:34 AM EDTCowen initiates coverage on Unum Therapeutics (NASDAQ: UMRX) with a Market Perform rating.
Analyst Eric Schmidt comments "Relative to 1st-gen T cell therapies, Unums Antibody-Coupled T cell Receptor (ACTR) platform seeks to provide a universal approach with the potential for greater tunability. While... More
